Full Text View
Tabular View
No Study Results Posted
Related Studies
Creatine for the Treatment of Amyotrophic Lateral Sclerosis
This study has been completed.
First Received: October 9, 2003   Last Updated: August 3, 2006   History of Changes
Sponsors and Collaborators: National Center for Complementary and Alternative Medicine (NCCAM)
Office of Dietary Supplements (ODS)
Information provided by: National Center for Complementary and Alternative Medicine (NCCAM)
ClinicalTrials.gov Identifier: NCT00070993
  Purpose

Creatine is a naturally occurring chemical involved in the production of energy in muscle. Abnormalities in creatine have been linked to the progression of degenerative neuromuscular diseases such as amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). This study will test whether taking creatine can improve the symptoms of ALS.


Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Drug: creatine monohydrate
Phase II

Genetics Home Reference related topics: amyotrophic lateral sclerosis
MedlinePlus related topics: Amyotrophic Lateral Sclerosis
Drug Information available for: Creatine Creatine monohydrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Efficacy Study
Official Title: Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis

Further study details as provided by National Center for Complementary and Alternative Medicine (NCCAM):

Estimated Enrollment: 110
Study Start Date: December 2002
Estimated Study Completion Date: May 2006
Detailed Description:

Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder selectively affecting motor neurons, resulting in progressive weakness.

Currently there is no known cure and a specific cause has not been identified. Creatine is a nutritional supplement that improves mitochondrial function and has been shown to protect motor neurons in animal models of ALS. Preliminary research indicates that creatine may also improve strength in patients with ALS. This study will determine the effect of creatine treatment on short-term muscle strength and long-term muscle deterioration in patients with ALS.

Participants in this study will be randomly assigned to receive either creatine or placebo. Participants will be enrolled in the study for 9 months.

Quantitative muscle testing will be done weekly for the first 3 weeks; participants will then be followed monthly for the next 4 months and bimonthly for the remainder of the 9-month study. The study will also monitor purposeful exercise to determine if this enhances the benefit of creatine usage on muscle strength. Pulmonary function testing will accompany the muscle testing to determine if creatine strengthens respiratory muscles, thereby enhancing pulmonary function.

  Eligibility

Ages Eligible for Study:   21 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Diagnosis of probable or definite ALS
  • At least 5 of 10 testable upper extremity muscle groups (shoulder and elbow extensors/flexors and grip) of Medical Research Council (MRC) grade 4 or better
  • At least 5 years from onset of symptoms

Exclusion Criteria

  • Requires tracheostomy ventilation
  • History of renal disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00070993

Locations
United States, California
California Pacific Medical Center
San Francisco, California, United States, 94115
United States, Illinois
Rush-Presbyterian St. Luke's Medical Center
Chicago, Illinois, United States, 60612
United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
United States, New Mexico
University of New Mexico - Medical Center
Albuquerque, New Mexico, United States, 87131
United States, Texas
University of Texas Health and Science Center
San Antonio, Texas, United States, 78284
United States, Virginia
University of Virginia Health System
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Investigators
Principal Investigator: Jeffrey Rosenfeld, MD Carolinas Medical Center
  More Information

No publications provided

Study ID Numbers: R01 AT000967-01
Study First Received: October 9, 2003
Last Updated: August 3, 2006
ClinicalTrials.gov Identifier: NCT00070993     History of Changes
Health Authority: United States: Food and Drug Administration

Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
ALS
Creatine

Study placed in the following topic categories:
Lou Gehrig's Disease
Neuromuscular Diseases
Spinal Cord Diseases
Amyotrophic Lateral Sclerosis
Central Nervous System Diseases
Sclerosis
Neurodegenerative Diseases
Degenerative Motor System Disease
Motor Neuron Disease

Additional relevant MeSH terms:
Pathologic Processes
Neuromuscular Diseases
Spinal Cord Diseases
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Central Nervous System Diseases
Sclerosis
Neurodegenerative Diseases
Motor Neuron Disease

ClinicalTrials.gov processed this record on May 07, 2009